US Edition
Antitrust Office Allows Biontech to Acquire Curevac
9 Articles
9 Articles
In the Corona pandemic they were still competitors: Now the Federal Cartel Office has given its permission to take over the Tübingen vaccine developer CureVac by the Mainz competitor BioNTech. [more]]>
During the Corona pandemic Biontech succeeds with his vaccine Comirnaty the very big litter. Competitor Curevac, on the other hand, does not make the breakthrough. Now it comes to the takeover. The last big hurdle for this is taken.
The Federal Cartel Office has approved the proposed acquisition of the Tübinger vaccine developer Curevac by the Mainz competitor Biontech.
The Federal Cartel Office does not see competition as being jeopardised by a takeover of Curevac by Biontech. The pharmaceutical company wants to spend more than one billion euros on the business.
mannheim24.de
Why do the competition guardians see no danger to innovation in the merger of Biontech and Curevac? The authority makes itself clear.
Why do the competition guardians see no danger to innovation in the merger of Biontech and Curevac? The authority makes itself clear.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
